Bayes Optimal Informer Sets for Early-Stage Drug Discovery

From MaRDI portal
Publication:6079751

DOI10.1111/BIOM.13637zbMATH Open1522.62282arXiv2011.06122OpenAlexW4213204524MaRDI QIDQ6079751FDOQ6079751

Michael A. Newton, Author name not available (Why is that?), Peng Yu, Author name not available (Why is that?)

Publication date: 30 October 2023

Published in: Biometrics (Search for Journal in Brave)

Abstract: An important experimental design problem in early-stage drug discovery is how to prioritize available compounds for testing when very little is known about the target protein. Informer based ranking (IBR) methods address the prioritization problem when the compounds have provided bioactivity data on other potentially relevant targets. An IBR method selects an informer set of compounds, and then prioritizes the remaining compounds on the basis of new bioactivity experiments performed with the informer set on the target. We formalize the problem as a two-stage decision problem and introduce the Bayes Optimal Informer SEt (BOISE) method for its solution. BOISE leverages a flexible model of the initial bioactivity data, a relevant loss function, and effective computational schemes to resolve the two-step design problem. We evaluate BOISE and compare it to other IBR strategies in two retrospective studies, one on protein-kinase inhibition and the other on anti-cancer drug sensitivity. In both empirical settings BOISE exhibits better predictive performance than available methods. It also behaves well with missing data, where methods that use matrix completion show worse predictive performance. We provide an R implementation of BOISE at https://github.com/wiscstatman/esdd/BOISE


Full work available at URL: https://arxiv.org/abs/2011.06122




Recommendations




Cites Work






This page was built for publication: Bayes Optimal Informer Sets for Early-Stage Drug Discovery

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6079751)